Latest news and press releases about IGC Pharma, Inc. (IGC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage.
Price
| Price | $0.27 |
| Market Cap | $27M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 4.20 |
| EV / EBITDA | -3.89 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -113.58% |
| Return on Invested Capital | -153.62% |
| Return on Assets | -83.03% |
| Gross Margin | 21.91% |
| Operating Margin | -986.82% |
| Net Margin | -702.14% |
Related companies: ANTX · BOLD · INTS · ITRM · NTRB · NXTC · PLUR
Explore sector: Healthcare · Biotechnology
More sections of IGC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks